Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Liabilities and Shareholders Equity: 2013-2017

Historic Liabilities and Shareholders Equity for Tvardi Therapeutics (TVRD) over the last 4 years, with Sep 2017 value amounting to $108.0 million.

  • Tvardi Therapeutics' Liabilities and Shareholders Equity rose 34.80% to $108.0 million in Q3 2017 from the same period last year, while for Sep 2017 it was $333.1 million, marking a year-over-year decrease of 13.49%. This contributed to the annual value of $63.8 million for FY2016, which is 42.44% down from last year.
  • As of Q3 2017, Tvardi Therapeutics' Liabilities and Shareholders Equity stood at $108.0 million, which was down 8.41% from $118.0 million recorded in Q2 2017.
  • In the past 5 years, Tvardi Therapeutics' Liabilities and Shareholders Equity ranged from a high of $118.0 million in Q2 2017 and a low of $18.1 million during Q4 2013.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $92.0 million (2016), whereas its average is $84.9 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 209.32% in 2014, then crashed by 57.56% in 2017.
  • Tvardi Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $18.1 million in 2013, then spiked by 209.32% to $55.9 million in 2014, then soared by 98.26% to $110.9 million in 2015, then crashed by 42.44% to $63.8 million in 2016, then surged by 34.80% to $108.0 million in 2017.
  • Its Liabilities and Shareholders Equity stands at $108.0 million for Q3 2017, versus $118.0 million for Q2 2017 and $43.3 million for Q1 2017.